Author details

Full Name

Mei-Yin C Polley

Affiliation

ORCID

Career Start Year

2008

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36993741	Targeted gene expression profiling predicts meningioma outcomes and radiotherapy responses.	Res Sq	2023
35601026	Two-Stage Adaptive Design for Prognostic Biomarker Signatures with a Survival Endpoint.	Statistics in Biopharmaceutical Research	2022
33389409	A clinical calculator to predict disease outcomes in women with triple-negative breast cancer.	Breast Cancer Res Treat	2021
33579807	Statistical Considerations in the Evaluation of Continuous Biomarkers.		2021
34218359	A clinical calculator to predict disease outcomes in women with hormone receptor-positive advanced breast cancer treated with first-line endocrine therapy.	Breast Cancer Res Treat	2021
34108182	Characteristics and Spatially Defined Immune (micro)landscapes of Early-stage PD-L1-positive Triple-negative Breast Cancer.	Clin Cancer Res	2021
33369635	Assessment of Ki67 in Breast Cancer: Updated Recommendations From the International Ki67 in Breast Cancer Working Group.	J Natl Cancer Inst	2021
31517559	Bleomycin use in the treatment of Hodgkin lymphoma (HL): toxicity and outcomes in the modern era.	Leukemia and Lymphoma	2020
32179748	The CCND1 c.870G risk allele is enriched in individuals of African ancestry with plasma cell dyscrasias.	Blood Cancer J	2020
32232481	Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial.	Blood	2020
32047850	Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients.	NPJ Breast Cancer	2020
33095682	Survival, Pathologic Response, and Genomics in CALGB 40601 (Alliance), a Neoadjuvant Phase III Trial of Paclitaxel-Trastuzumab With or Without Lapatinib in HER2-Positive Breast Cancer.	J Clin Oncol	2020
32569799	A Validated T Cell Radiomics Score Is Associated With Clinical Outcomes Following Multisite SBRT and Pembrolizumab.	International Journal of Radiation Oncology Biology Physics	2020
31339827	Randomized Trial of Standard Adjuvant Chemotherapy Regimens Versus Capecitabine in Older Women With Early Breast Cancer: 10-Year Update of the CALGB 49907 Trial.	J Clin Oncol	2019
31602395	Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer.	NPJ Breast Cancer	2019
32923846	Early-Phase Platform Trials: A New Paradigm for Dose Finding and Treatment Screening in the Era of Precision Oncology.	JCO Precision Oncology	2019
32923845	Phase III Precision Medicine Clinical Trial Designs That Integrate Treatment and Biomarker Evaluation.	JCO Precision Oncology	2019
31174236	Randomized trial of ofatumumab and bendamustine versus ofatumumab, bendamustine, and bortezomib in previously untreated patients with high-risk follicular lymphoma: CALGB 50904 (Alliance).	Cancer	2019
30784598	Mass Cytometry Analysis Reveals that Specific Intratumoral CD4 T Cell Subsets Correlate with Patient Survival in Follicular Lymphoma.	Cell Reports	2019
30783078	Hyperhaploid plasma cell myeloma characterized by poor outcome and monosomy 17 with frequently co-occurring TP53 mutations.	Blood Cancer Journal	2019
30939090	Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303.	J Clin Oncol	2019
30305608	Differences in genomic abnormalities among African individuals with monoclonal gammopathies using calculated ancestry.	Blood Cancer J	2018
28913760	Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer.	Breast Cancer Res Treat	2018
28776405	Power estimation in biomarker studies where events are already observed.	Clinical Trials	2017
25698062	An international study to increase concordance in Ki67 scoring.	Mod Pathol	2015
25003314	Immunotherapy and radiation therapy: considerations for successfully combining radiation into the paradigm of immuno-oncology drug development.	Radiation Research	2014
25417040	Comparison of confidence interval methods for an intra-class correlation coefficient (ICC).	BMC Medical Research Methodology	2014
25263614	Two-stage adaptive cutoff design for building and validating a prognostic biomarker signature.	Stat Med	2014
23680692	Circulating levels of immune and inflammatory markers and long versus short survival in early-stage lung cancer.	Ann Oncol	2013
24000377	Development of omics-based clinical tests for prognosis and therapy selection: the challenge of achieving statistical robustness and clinical utility.	Clinical Trials	2013
24203987	An international Ki67 reproducibility study.	J Natl Cancer Inst	2013
24136891	Statistical and practical considerations for clinical evaluation of predictive biomarkers.	Journal of the National Cancer Institute	2013
24132288	Criteria for the use of omics-based predictors in clinical trials.	Nature	2013
24228635	Criteria for the use of omics-based predictors in clinical trials: explanation and elaboration.	BMC Med	2013
21826561	Pediatric intracranial ependymoma: the roles of surgery, radiation and chemotherapy.	J Neurooncol	2012
22293178	Heparan sulfate sulfatase SULF2 regulates PDGFRÎ± signaling and growth in human and mouse malignant glioma.	J Clin Invest	2012
22869885	Randomized phase II trial designs with biomarkers.	Journal of Clinical Oncology	2012
21590790	Practical modifications to the time-to-event continual reassessment method for phase I cancer trials with fast patient accrual and late-onset toxicities.	Statistics in Medicine	2011
21036812	Assessment of perfusion MRI-derived parameters in evaluating and predicting response to antiangiogenic therapy in patients with newly diagnosed glioblastoma.	Neuro Oncol	2011
21297128	Serial analysis of imaging parameters in patients with newly diagnosed glioblastoma multiforme.	Neuro Oncol	2011
21417701	An extent of resection threshold for newly diagnosed glioblastomas.	J Neurosurg	2011
21142749	Impact of bevacizumab chemotherapy on craniotomy wound healing.	J Neurosurg	2011
20932098	Assessment of morbidity following resection of cingulate gyrus gliomas. Clinical article.	J Neurosurg	2011
21317208	Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide.	Neuro Oncol	2011
21497989	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: efficacy and underlying mechanisms.	Cancer Lett	2011
21311950	Identifying the needs of brain tumor patients and their caregivers.	J Neurooncol	2011
20563833	Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study.	J Neurooncol	2011
20635853	Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. Clinical article.	J Neurosurg	2011
21896554	Phase II and pharmacogenomics study of enzastaurin plus temozolomide during and following radiation therapy in patients with newly diagnosed glioblastoma multiforme and gliosarcoma.	Neuro Oncol	2011
21969507	Conditional probability of survival in patients with newly diagnosed glioblastoma.	J Clin Oncol	2011